Emerging trends in the epidemiology of melanoma

British Journal of Dermatology

Volumn 170, Issue 1, 2014, Pages 11-19

  Nikolaou, V ^a   Stratigos, A J ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER INCIDENCE; CANCER MORTALITY; CANCER PROGNOSIS; CHILDHOOD CANCER; CUTANEOUS MELANOMA; DISEASE ASSOCIATION; ENVIRONMENTAL FACTOR; GENETIC RISK; HUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RADIATION EXPOSURE; REVIEW; RISK FACTOR; ULTRAVIOLET RADIATION; EPIDEMIOLOGY; FEMALE; GENETIC PREDISPOSITION; INCIDENCE; MALE; MELANOMA; MORTALITY; PHENOTYPE; PROGNOSIS; SEX RATIO; SKIN NEOPLASMS; SUNBATHING;

FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INCIDENCE; MALE; MELANOMA; PARKINSON DISEASE; PHENOTYPE; PROGNOSIS; RISK FACTORS; SEX DISTRIBUTION; SKIN NEOPLASMS; SUNBATHING; ULTRAVIOLET RAYS;

EID: 84887847173     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12492     Document Type: Review

References (91)

1. de Vries E, van de Poll-Franse LV, Louwman WJ, et al,. Predictions of skin cancer incidence in the Netherlands up to 2015. Br J Dermatol 2005; 152: 481-8.
2. Diffey BL,. The future incidence of cutaneous melanoma within the U.K. Br J Dermatol 2004; 151: 868-72.
3. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
4. American Cancer Society. Cancer Facts and Figures. Atlanta, GA: American Cancer Society, 2012.
5. Stang A, Stang K, Stegmaier C, et al,. Skin melanoma in Saarland: incidence, survival and mortality 1970-1996. Eur J Cancer Prev 2001; 10: 407-15.
6. Balzi D, Carli P, Geddes M,. Malignant melanoma in Europe: changes in mortality rates (1970-90) in European Community countries. Cancer Causes Control 1997; 8: 85-92.
7. Crocetti E, Carli P,. Changes from mid-1980s to late 1990s among clinical and demographic correlates of melanoma thickness. Eur J Dermatol 2003; 13: 72-5.
8. van der Spek-Keijser LM, van der Rhee HJ, Toth G, et al,. Site, histological type, and thickness of primary cutaneous malignant melanoma in western Netherlands since 1980. Br J Dermatol 1997; 136: 565-71.
9. Garbe C, McLeod GR, Buettner PG,. Time trends of cutaneous melanoma in Queensland, Australia and Central Europe. Cancer 2000; 89: 1269-78.
10. Culos KA, Cuellar S,. Novel targets in the treatment of advanced melanoma: new first-line treatment options. Ann Pharmacother 2013; 47: 519-26.
11. Garbe C, Leiter U,. Melanoma epidemiology and trends. Clin Dermatol 2009; 27: 3-9.
12. MacLennan R, Green AC, McLeod GR, et al,. Increasing incidence of cutaneous melanoma in Queensland, Australia. J Natl Cancer Inst 1992; 84: 1427-32.
13. Kohler BA, Ward E, McCarthy BJ, et al,. Annual report to the nation on the status of cancer, 1975-2007, featuring tumors of the brain and other nervous system. J Natl Cancer Inst 2011; 103: 714-36.
14. Jemal A, Saraiya M, Patel P, et al,. Recent trends in cutaneous melanoma incidence and death rates in the United States, 1992-2006. J Am Acad Dermatol 2011; 65: S17-25.
15. Erdmann F, Lortet-Tieulent J, Schüz J, et al,. International trends in the incidence of malignant melanoma 1953-2008-are recent generations at higher or lower risk? Int J Cancer 2013; 132: 385-400.
16. Akushevich I, Kravchenko J, Ukraintseva S, et al,. Time trends of incidence of age-associated diseases in the US elderly population: Medicare-based analysis. Age Ageing 2013; 42: 494-500.
17. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al,. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013; 49: 1374-403.
18. De Vries E, Bray FI, Coebergh JWC, Parkin DM,. Changing epidemiology of malignant cutaneous melanoma in Europe 1953-1997; rising trends in incidence and mortality but recent stabilizations in Western Europe and decreases in Scandinavia. Int J Cancer 2003; 107: 119-26.
19. Forsea AM, de Marmol V, de Vries E, et al,. Melanoma incidence and mortality in Europe: new estimates, persistent disparities. Br J Dermatol 2012; 167: 1124-30.
20. Geller AC, Miller DR, Annas GD, et al,. Melanoma incidence and mortality among US whites, 1969-1999. JAMA 2002; 288: 1719-20.
21. Marks R,. The changing incidence and mortality of melanoma in Australia. Recent Results Cancer Res 2002; 160: 113-21.
22. Purdue MP, Freeman LE, Anderson WF, Tucker MA,. Recent trends in incidence of cutaneous melanoma among US Caucasian young adults. J Invest Dermatol 2008; 128: 2905-8.
23. Bradford PT, Anderson WF, Purdue MP, et al,. Rising melanoma incidence rates of the trunk among younger women in the United States. Cancer Epidemiol Biomarkers Prev 2010; 19: 2401-6.
24. Liu F, Bessonova L, Taylor TH, et al,. A unique gender difference in early onset melanoma implies that in addition to ultraviolet light exposure other causative factors are important. Pigment Cell Melanoma Res 2013; 26: 128-35.
25. Hoersch B, Leiter U, Garbe C,. Is head and neck melanoma a distinct entity? A clinical registry-based comparative study in 5702 patients with melanoma. Br J Dermatol 2006; 155: 771-7.
26. Whiteman DC, Stickley M, Watt P, et al,. Anatomic site, sun exposure, and risk of cutaneous melanoma. J Clin Oncol 2006; 24: 3172-7.
27. Olsen CM, Zens MS, Green AC, et al,. Biologic markers of sun exposure and melanoma risk in women: pooled case-control analysis. Int J Cancer 2011; 129: 713-23.
28. Chang YM, Barrett JH, Bishop DT, et al,. Sun exposure and melanoma risk at different latitudes: a pooled analysis of 5700 cases and 7216 controls. Int J Epidemiol 2009; 38: 814-30.
29. Baade PD, English DR, Youl PH, et al,. The relationship between melanoma thickness and time to diagnosis in a large population-based study. Arch Dermatol 2006; 142: 1422-7.
30. Linos E, Swetter SM, Cockburn MG, et al,. Increasing burden of melanoma in the United States. J Invest Dermatol 2009; 129: 1666-74.
31. Tryggvadõttir L, Gislum M, Hakulinen T, et al,. Trends in the survival of patients diagnosed with malignant melanoma of the skin in the Nordic countries 1964-2003 followed up to the end of 2006. Acta Oncol 2010; 49: 665-72.
32. Hollestein LM, van den Akker SA, Nijsten T, et al,. Trends of cutaneous melanoma in the Netherlands: increasing incidence rates among all Breslow thickness categories and rising mortality rates since 1989. Ann Oncol 2012; 23: 524-30.
33. Murray CS, Stockton DL, Doherty VR,. Thick melanoma: the challenge persists. Br J Dermatol 2005; 152: 104-9.
34. Ries LAG, Eisner MP, Kosary CL, et al,. SEER Cancer Statistics Review, 1975-2002. Bethesda, MD: National Cancer Institute, 2004. Available at: http://seer.cancer.gov/csr/1975-2002/ (based on November 2004 SEER data submission, posted to the SEER website 2005; last accessed 21 August 2013).
35. Geller AC, Elwood M, Swetter SM, et al,. Factors related to the presentation of thin and thick nodular melanoma from a population-based cancer registry in Queensland Australia. Cancer 2009; 115: 1318-27.
36. Lasithiotakis K, Leiter U, Meier F, et al,. Age and gender are significant independent predictors of survival in primary cutaneous melanoma. Cancer 2008; 112: 1795-804.
37. Balch CM, Soong SJ, Gershenwald JE, et al,. Prognostic factors analysis of 17 600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001; 19: 3622-34.
38. De Vries E, Nijsten TEC, Visser O, et al,. Superior survival of females among 10 538 Dutch melanoma patients is independent of Breslow thickness, histologic type and tumor site. Ann Oncol 2008; 19: 583-9.
39. Joosse A, de Vries E, Eckel R, et al,. Gender differences in melanoma survival: female patients have a decreased risk of metastasis. J Invest Dermatol 2011; 131: 719-26.
40. Gandini S, Iodice S, Koomen E, et al,. Hormonal and reproductive factors in relation to melanoma in women: current review and meta-analysis. Eur J Cancer 2011; 47: 2607-17.
41. Naldi L, Altieri A, Imberti GL, et al,. Cutaneous malignant melanoma in women. Phenotypic characteristics, sun exposure, and hormonal factors: a case-control study from Italy. Ann Epidemiol 2005; 15: 545-50.
42. Lens MB, Reiman T, Husain AF,. Use of tamoxifen in the treatment of malignant melanoma. Cancer 2003; 98: 1355-61.
43. Kanavy HE, Gerstenblith MR,. Ultraviolet radiation and melanoma. Semin Cutan Med Surg 2011; 30: 222-8.
44. Holman CD, Armstrong BK,. Cutaneous malignant melanoma and indicators of total accumulated exposure to the sun: an analysis separating histogenetic types. J Natl Cancer Inst 1984; 73: 75-82.
45. Autier P, Doré JF, Gefeller O, et al,. Melanoma risk and residence in sunny areas. EORTC Melanoma Co-operative Group. European Organization for Research and Treatment of Cancer. Br J Cancer 1997; 76: 1521-4.
46. Moan J, Dahlback A,. The relationship between skin cancers, solar radiation and ozone depletion. Br J Cancer 1992; 65: 916-21.
47. Bulliard JL, Cox B, Elwood JM,. Latitude gradients in melanoma incidence and mortality in the non-Maori population of New Zealand. Cancer Causes Control 1994; 5: 234-40.
48. Elwood JM, Jopson J,. Melanoma and sun exposure: an overview of published studies. Int J Cancer 1997; 73: 198-203.
49. Gandini S, Sera F, Cattaruzza MS, et al,. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer 2005; 41: 45-60.
50. Curtin JA, Fridlyand J, Kageshita T, et al,. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005; 353: 2135-47.
51. Thomas NE, Edmiston SN, Alexander A, et al,. Number of nevi and early-life ambient UV exposure are associated with BRAF-mutant melanoma. Cancer Epidemiol Biomarkers Prev 2007; 16: 991-7.
52. Besaratinia A, Pfeifer GP,. Sunlight ultraviolet irradiation and BRAF V600 mutagenesis in human melanoma. Hum Mutat 2008; 29: 983-91.
53. Edwards RH, Ward MR, Wu H, et al,. Absence of BRAF mutations in UV protected mucosal melanomas. J Med Genet 2004; 41: 270-2.
54. Handolias D, Salemi R, Murray W, et al,. Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure. Pigment Cell Melanoma Res 2010; 23: 210-15.
55. Curtin JA, Busam K, Pinkel D, Bastian BC,. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006; 24: 4340-6.
56. Veierød MB, Adami H-O, Lund E, et al,. Sun and solarium exposure and melanoma risk: effects of age, pigmentary characteristics, and nevi. Cancer Epidemiol Biomarkers Prev 2010; 19: 111-20.
57. Boniol M, Autier P, Boyle P, Gandini S,. Cutaneous melanoma attributable to sunbed use: systematic review and meta-analysis. BMJ 2012; 345: e4757.
58. Zhang M, Qureshi AA, Geller AC, et al,. Use of tanning beds and incidence of skin cancer. J Clin Oncol 2012; 30: 1588-93.
59. Dal H, Boldemann C, Lindelöf B,. Does relative melanoma distribution by body site 1960-2004 reflect changes in intermittent exposure and intentional tanning in the Swedish population? Eur J Dermatol 2007; 17: 428-34.
60. Gandini S, Sera F, Cattaruzza MS, et al,. Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur J Cancer 2005; 41: 28-44.
61. Olsen CM, Zens MS, Stukel TA, et al,. Nevus density and melanoma risk in women: a pooled analysis to test the divergent pathway hypothesis. Int J Cancer 2009; 124: 937-44.
62. Gandini S, Sera F, Cattaruzza MS, et al,. Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. Eur J Cancer 2005; 41: 2040-59.
63. Olsen CM, Carroll HJ, Whiteman DC,. Estimating the attributable fraction for melanoma: a meta-analysis of pigmentary characteristics and freckling. Int J Cancer 2010; 127: 2430-45.
64. Olsen CM, Carroll HJ, Whiteman DC,. Familial melanoma: a meta-analysis and estimates of attributable fraction. Cancer Epidemiol Biomarkers Prev 2010; 19: 65-73.
65. Udayakumar D, Mahato B, Gabree M, Tsao H,. Genetic determinants of cutaneous melanoma predisposition. Semin Cutan Med Surg 2010; 29: 190-5.
66. Bishop DT, Demenais F, Goldstein AM, et al,. Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst 2002; 94: 894-903.
67. Wiesner T, Obenauf AC, Murali R, et al,. Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet 2011; 43: 1018-21.
68. Valverde P, Healy E, Jackson I, et al,. Variants of the melanocyte-stimulating hormone receptor gene are associated with red hair and fair skin in humans. Nat Genet 1995; 11: 328-30.
69. Williams PF, Olsen CM, Hayward NK, Whiteman DC,. Melanocortin 1 receptor and risk of cutaneous melanoma: a meta-analysis and estimates of population burden. Int J Cancer 2011; 129: 1730-40.
70. Barrett JH, Iles MM, Harland M, et al,. Genome-wide association study identifies three new melanoma susceptibility loci. Nat Genet 2011; 43: 1108-13.
71. Bishop DT, Demenais F, Iles MM, et al,. Genome-wide association study identifies three loci associated with melanoma risk. Nat Genet 2009; 41: 920-5.
72. Macgregor S, Montgomery GW, Liu JZ, et al,. Genome-wide association study identifies a new melanoma susceptibility locus at 1q21.3. Nat Genet 2011; 43: 1114-18.
73. Duffy DL, Iles MM, Glass D, et al,. IRF44 variants have age-specific effects on nevus count and predispose to melanoma. Am J Hum Genet 2010; 87: 6-16.
74. Chatzinasiou F, Lill CM, Kypreou K, et al,. Comprehensive field synopsis and systematic meta-analyses of genetic association studies in cutaneous melanoma. J Natl Cancer Inst 2011; 103: 1227-35.
75. Yokoyama S, Woods SL, Boyle GM, et al,. A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature 2011; 480: 99-103.
76. Bertolotto C, Lesueur F, Giuliano S, et al,. A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature 2011; 480: 94-8.
77. O'Rorke MA, Black C, Murray LJ, et al,. Do perinatal and early life exposures influence the risk of malignant melanoma? A Northern Ireland birth cohort analysis. Eur J Cancer 2013; 49: 1109-16.
78. Meysjebs FL, Yang S,. Thinking about the role (largely ignored) of heavy metals in cancer prevention: hexavalent chromium and melanoma as a case in point. Recent Results Cancer Res 2011; 188: 65-74.
79. Dennis LK, Lynch CF, Sandler DP, Alavanja MC,. Pesticide use and cutaneous melanoma in pesticide applicators in the agricultural health study. Environ Health Perspect 2010; 118: 812-17.
80. de Vries E, Trakatelli M, Kalabalikis D, et al,. Known and potential new risk factors for skin cancer in European populations: a multicenter case-control study. Br J Dermatol 2012; 167 (Suppl. 2): 1-13.
81. Song F, Qureshi AA, Gao X, et al,. Smoking and risk of skin cancer: a prospective analysis and a meta-analysis. Int J Epidemiol 2012; 41: 1694-705.
82. Johannesdottir SA, Chang ET, Mehnert F, et al,. Nonsteroidal anti-inflammatory drugs and the risk of skin cancer. Cancer 2012; 118: 4768-76.
83. Gamba CA, Swetter SM, Stefanick ML, et al,. Aspirin is associated with lower melanoma risk among postmenopausal Caucasian women: the Women's Health Initiative. Cancer 2013; 119: 1562-9.
84. Hu H, Xie Y, Yang G, et al,. Nonsteroidal anti-inflammatory drug use and the risk of melanoma: a meta-analysis. Eur J Cancer Prev 2013 Mar 30 (Epub ahead of print).
85. Long MD, Martin CF, Pipkin CA, et al,. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology 2012; 143: 390-9.
86. Pappo AS, Armstrong GT, Liu W, et al,. Melanoma as a subsequent neoplasm in adult survivors of childhood cancer: a report from the Childhood Cancer Survivor study. Pediatr Blood Cancer 2013; 60: 461-6.
87. Bertoni JM, Arlette JP, Fernandez HH, et al,. North American Parkinson's and Melanoma Survey Investigators. Increased melanoma risk in Parkinson disease: a prospective clinicopathological study. Arch Neurol 2010; 67: 347-52.
88. Olsen JH, Friis S, Frederiksen K,. Malignant melanoma and other types of cancer preceding Parkinson disease. Epidemiology 2006; 17: 582-7.
89. Vermeij JD, Winogrodzka A, Trip J, Weber WE,. Parkinson's disease, levodopa-use and the risk of melanoma. Parkinsonism Relat Disord 2009; 15: 551-3.
90. Zanetti R, Loria D, Rosso S,. Melanoma, Parkinson's disease and levodopa: causal or spurious link? A review of the literature. Melanoma Res 2006; 16: 201-6.
91. Pan T, Li X, Jankovic J,. The association between Parkinson's disease and melanoma. Int J Cancer 2011; 128: 2251-60.